159724-49-9

Basic information

• Product Name: Ethanone,1-(2,3-diaminophenyl)-
• Synonyms: Ethanone,1-(2,3-diaminophenyl)-;Ethanone, 1-(2,3-diaminophenyl)- (9CI)
• CAS NO: 159724-49-9
• Molecular Formula: C₈H₁₀N₂O
• Molecular Weight: 150.1778
• Product Categories: ACETYLGROUP;AMINEPRIMARY
• Mol File: 159724-49-9.mol
• Article Data: 3

Chemical Properties

• Melting Point: 121-122.5 °C
• Boiling Point: 336.9±22.0 °C(Predicted)
• Appearance: /
• Density: 1.196±0.06 g/cm3(Predicted)
• PKA: 2.98±0.10(Predicted)
• CAS DataBase Reference: Ethanone,1-(2,3-diaminophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone,1-(2,3-diaminophenyl)-(159724-49-9)
• EPA Substance Registry System: Ethanone,1-(2,3-diaminophenyl)-(159724-49-9)

Safety Data

• Hazardous Substances Data: 159724-49-9(Hazardous Substances Data)

Upstream product

• 7463-31-2 3-Acetamidoacetophenone 
• 99-03-6 1-(3-aminophenyl)ethanone 
• 5234-26-4 N-(2-acetylphenyl)acetamide 
• 194784-10-6 acetic acid-(2-acetyl-6-nitro-anilide) 
• 92642-18-7 N-(3-acetyl-2-nitrophenyl)acetamide 
• 20864-49-7 2-amino-3-nitroacetophenone 
• 10202-87-6 1-(3-amino-2-nitrophenyl)ethanone 

Downstream Products

• 1438559-38-6 phenyl(quinoxalin-5-yl)methanone 
• 89334-34-9 1-(quinoxalin-5-yl)ethanone 
• 201412-00-2 4-acetyl-2-benzylbenzimidazole 
• 201411-97-4 4-acetyl-2-(2-phenylethyl)benzimidazole 

Relevant articles and documents

Direct exchange of a ketone methyl or aryl group to another aryl group through ciC bond activation assisted by rhodium chelation

Swapped: Commercially available quinolinone derivatives (1 or 2, see scheme) were reacted with arylboronic acids in the presence of a RhI complex to give aryl(quinolin-8-yl)methanone products 3 in medium to good yields. A mechanism that involves the in situ oxidation of RhI to RhIII by O2 in the presence of CuI was proposed. Copyright

Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation

Indazole compounds that modulate and/or inhibit cell proliferation, such as the activity of protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating, e.g., kinases-dependent diseases to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.